Zongertinib in HER2-Mutant NSCLC: 71% Response Rate from Beamion LUNG-1 Trial | AACR 2025 скачать в хорошем качестве

Zongertinib in HER2-Mutant NSCLC: 71% Response Rate from Beamion LUNG-1 Trial | AACR 2025

ARTICLE: https://oncologytube.com/zongertinib-... In this exclusive OncologyTube.com video, we explore the clinical data on Zongertinib (BI 1810631), an oral HER2-selective tyrosine kinase inhibitor (TKI), for HER2-mutant non-small-cell lung cancer (NSCLC). Presented by Dr. John Heymach from MD Anderson at AACR 2025, the Beamion LUNG-1 trial results show a 71% overall response rate (ORR), 12.4 months median progression-free survival (PFS), and a 41% intracranial ORR in patients with brain metastases. Zongertinib’s EGFR-sparing mechanism is associated with reduced toxicities, such as rash and diarrhea, with no reported interstitial lung disease (ILD) and only 17% Grade 3 or higher toxicities compared to 40% with trastuzumab deruxtecan. The FDA has granted priority review, with a decision expected in Q3 2025, and the BEAMION LUNG-2 trial is evaluating its potential as a frontline therapy. This video covers the trial findings and their relevance for HER2-mutant NSCLC patients. Timestamps: 0:00 – Introduction: Exclusive Video from OncologyTube.com 0:02 – Zongertinib’s 71% Overall Response Rate in HER2-Mutant NSCLC 0:10 – AACR 2025 Presentation Highlights 0:15 – Beamion LUNG-1 Trial: 12.4 Months Median PFS 0:19 – 41% Intracranial Response Rate in Brain Metastases 0:25 – FDA Priority Review: Decision Expected Q3 2025 0:32 – Toxicity Comparison with Trastuzumab Deruxtecan 0:36 – Median Duration of Response: 14.1 Months 0:40 – Potential Option for HER2-Mutant NSCLC Patients 0:45 – Addressing Brain Metastases in NSCLC 0:54 – EGFR-Sparing Mechanism and Reduced Side Effects 1:00 – No Interstitial Lung Disease (ILD) Reported 1:05 – What Makes Zongertinib an Oral TKI Option 1:10 – BEAMION LUNG-2: Exploring Frontline Therapy Use 1:18 – Presented by Dr. John Heymach at AACR 2025 1:24 – Published in the New England Journal of Medicine 1:31 – Relevance for HER2-Mutant NSCLC Patients 1:36 – Subscribe & Visit OncologyTube.com for More Cancer Updates